Month: May 2020

The information was released for public disclosure on May 29, 2020, at 08:20 CETCellaVision’s President and CEO, Zlatko Rihter, has informed the Board of Directors that he wishes to resign as CEO of the company in order to take on the position as President and CEO of the medical technology company Mölnlycke Health Care AB. Zlatko Rihter has been CEO of CellaVision since January 1, 2015.Zlatko will continue in his current role during the notice period and leave his assignment by November 28, 2020 at the latest. The Board has therefore initiating a recruitment process to find his successor.“During his almost six years as CEO, Zlatko Rihter has very successfully developed CellaVision to the strong company we see today. CellaVision has fundamentally changed to a company with a completely different breadth in the customer offering and...

Informationen lämnades för offentliggörande 2020-05-29 kl. 08.20CellaVisions VD och koncernchef, Zlatko Rihter, har meddelat styrelsen att han önskar sluta som VD för bolaget för att istället tillträdda rollen som VD och koncernchef för det medicintekniska bolaget Mölnlycke Health Care AB. Zlatko Rihter har varit VD för CellaVision sedan den 1 januari 2015.Zlatko kommer att fortsätta i sin nuvarande roll under uppsägningstiden och lämnar sitt uppdrag senast den 28 november 2020. Styrelsen initierar därmed omgående arbetet med att finna hans efterträdare.”Zlatko Rihter har under sina snart sex år som VD mycket framgångsrikt utvecklat och drivit CellaVision till det starka bolag vi ser idag. CellaVision har förändrats i grunden till ett bolag med en helt annan bredd i kunderbjudande och geografisk närvaro vilket resulterar i helt andra...

Hørsholm, Denmark – May 29, 2020 – Oncology Venture A/S (OV:ST) (“Oncology Venture”) today announces the Q1 2020 Report for the period January – March 2020. The report is available as an attached document and on the company’s website.           Comment from CEO Steve Carchedi“The first quarter of 2020 has truly been an unprecedented business environment, as the Covid-19 pandemic rapidly changed the world around us. However, I am pleased to report that Oncology Venture has succeeded in continuing to execute our strategy as intended. Most importantly, we have announced that we received feedback from the U.S. FDA regarding a potential path to approval for Dovitinib. All in all, this feedback was very encouraging for us, and we are excited to adapt our plans according to the FDA’s input as speedily as we can. In addition, we have been able...

The Management Board of joint stock company “GRINDEKS”, registration number: 40003034935, legal address: 53 Krustpils street, Riga, Latvia, LV-1057 (hereafter – the Company), calls up and announces that Annual General Meeting of Shareholders of the Company will take place on 30 June 2020 at 12.00 at premises of the Company, 53 Krustpils street, Riga, Latvia. Shareholder Registration will be open from 11.30.Agenda:Reports of the Management Board, the Supervisory Council and statement of the Sworn auditor.Approval of the Annual report for the year 2019.Distribution of the profit for the year 2019.Election of the auditor and determination of the remuneration for the auditor.Election of the Audit Committee and determination of the remuneration for the Audit Committee.Approval of renumeration policy for the Management Board and the Supervisory...

Akciju sabiedrības „GRINDEKS”, vienotais reģ. nr. 40003034935, juridiskā adrese: Krustpils iela 53, Rīga, LV-1057 (tālāk tekstā – Sabiedrība), valde sasauc un paziņo, ka Sabiedrības kārtējā akcionāru sapulce notiks 2020. gada 30. jūnijā plkst. 12.00 Sabiedrības telpās, Krustpils ielā 53, Rīgā, akcionāru reģistrācija no plkst. 11.30.Darba kārtība:Valdes, padomes ziņojumi un zvērināta revidenta atzinums.2019. gada pārskata apstiprināšana. 2019. gada peļņas izlietošana.Revidenta ievēlēšana un atlīdzības noteikšana revidentam.Revīzijas komitejas vēlēšanas un atlīdzības noteikšana revīzijas komitejai.Valdes un padomes atalgojuma politikas apstiprināšana.Ņemot vērā Covid-19 pandēmiju, lai aizsargātu akcionāru, Sabiedrības darbinieku un sabiedrības veselību kopumā, aicinām visus akcionārus akcionāru sapulcē piedalīties rakstveidā, pirms akcionāru...

Rättelsen avser att pressmeddelandet med rubriken “Årsstämma i PolyPlank AB” som publicerades igår den 28 maj 2020, felaktigt klassades som information som är skyldig att offentliggöras enligt EU:s marknadsmissbruksförordning (“MAR”).Nedan följer en rättad version.PolyPlank AB (publ) har hållit årsstämma på Bolagets kontor, Färjestaden, Öland. Samtliga beslut togs enligt styrelsens förslag.Stämman beslutade att fastställa de i årsredovisningen intagna resultat- och balansräkningarna samt koncernresultaträkning och koncernbalansräkning.Stämman beslutade att behandla det uppkomna resultatet i enlighet med styrelsens förslag i årsredovisningen.Stämman beviljade styrelsens ledamöter och verkställande direktören ansvarsfrihet för förvaltningen under det gångna året.Stämman beslutade att antalet ordinarie ledamöter skall vara...

On May 28 JSC “Latvijas Gāze” organized its Investor Conference Online Webinar. During the webinar the Vice-Chairman of Management Board Sebastian Groeblinghoff analyzed “Latvijas Gāze” Group’s unaudited financial results of 3 months 2020 and informed about other key initiatives of the Group.The recorded webinar is available online: https://bit.ly/36Atahd, and the presentation, demonstrated during the webinar, is available in the attachment.Additional information:Madara VentereHead of Finance and accounting divisionPhone: + (371) 67 369 281E-mail: investor.relations@lg.lvwww.lg.lvAttachment2020-05-28_Latvijas Gaze Unaudited Q1 Results 2020_Investor_Webinar

28. maijā AS “Latvijas Gāze” aizvadīja virtuālo konferenci investoriem. Konferences laikā AS “Latvijas Gāze” valdes priekšsēdētāja vietnieks Sebastians Grēblinghofs analizēja AS “Latvijas Gāze” koncerna 2020. gada 1. ceturkšņa neauditētos finanšu rezultātus, kā arī informēja par citām aktualitātēm uzņēmumā.Virtuālās konferences ieraksts ir pieejams šeit: https://bit.ly/36Atahd, savukārt virtuālās konferences laikā demonstrētā prezentācija ir pievienota paziņojuma pielikumā.Papildus informācija:Madara VentereFinanšu un grāmatvedības daļas vadītājaTel.: + (371) 67 369 281E-pasts: investor.relations@lg.lvwww.lg.lvPielikums2020-05-28_Latvijas Gaze Unaudited Q1 Results 2020_Investor_Webinar

The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancerThe first treatments could begin in the next few weeks, with the objective of first results late 2020/early 2021PARIS, May 29, 2020 (GLOBE NEWSWIRE) — Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced that the REVocan1 phase 1b/2 designed to evaluate the effect of AsiDNA™, Onxeo’s first-in-class DDR inhibitor, on the acquired resistance to PARP inhibitor (PARPi) niraparib for 2nd line maintenance treatment of relapsed ovarian cancer, has received approval from the French National...

January–March 2020First Quarter 2020Revenue decreased by MEUR 42.8 (–20.1%) to MEUR 170.6. The decrease is due to the negative impact of the COVID-19 outbreak. At the end of the quarter, 170 hotels were closed due to the pandemic. On a like-for-like basis, including hotels under renovation (“LFL&R”), Revenue decreased by MEUR 41.7 (–20.1%).Reported RevPAR for leased and managed hotels decreased by 20.7%. RevPAR LFL&R decreased by 20.1%.EBITDA decreased by MEUR 30.5 to MEUR –5.3. The results in March was severely impacted by the revenue drop due to COVID-19. The cost base was significantly reduced in the hotels as of March, while the full impact of the measures taken to reduce central costs is only visible as from April. The EBITDA margin was–3.1% (11.8%).EBIT decreased by MEUR 34.5 to MEUR –27.4. In addition to the EBITDA decrease,...